Emerging applications of long-read sequencing in hematological malignancies: highlights from the 2025 ASH annual meeting
Abstract
Long-read sequencing (LRS) is rapidly advancing and demonstrates considerable promise in hematological malignancies. At the 2025 ASH meeting, numerous studies highlighted advances in applying LRS across diverse hematological malignancies. Rapid LRS-based whole-genome sequencing and adaptive sampling enable real-time subtype assignment, detection of SNVs, CNVs, and gene fusions, as well as methylation-based classification. By spanning repetitive and structurally complex regions, LRS enhances genetic subtyping and uncovers clinically relevant structural variants often missed by short-read technologies. Full-length and single-cell RNA sequencing further resolve isoforms, splicing programs, and fusion transcripts within their clonal contexts, supporting precision therapy and refined risk stratification. As accuracy improves and costs decline, LRS is poised for broader integration into routine clinical diagnostics.
Read the paper
Related studies
- Regulation of nucleolus assembly by non-coding RNA polymerase II transcripts
- For a Healthy Histone Code, a Little SUMO in the Tail Keeps the Acetyl Away
- Discovering a binary CTCF code with a little help from BORIS
- Article Commentary: Stabilizing the Code–-Methods to Preserve RNA Prove Their Worth
- Foreword to the Special Issue for the RINTC (The Implicit Seismic Risk of Code-Conforming Structures) Project
- Commentary: Promoting Health and Well-being in Pediatric Primary Care Settings: Using Health and Behavior Codes at Routine Well-child Visits
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.